MaaT Pharma Aktie
7,64EUR | -0,12EUR | -1,55% |
WKN DE: A3C7A5 / ISIN: FR0012634822
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 56,47 |
BPIFrance Investissement SAS | 20,13 |
Seventure Partners SA | 18,63 |
Symbiosis LLC /DC/ | 14,57 |
Crédit Mutuel Impact SA | 10,15 |
Pharcor SAS | 8,82 |
Hervé Affagard, EMBA | 1,43 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 0 | 0 | 0 | 0 | 0 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
Bilanz (in Mio. EUR) - Aktiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 7 | 22 | 47 | 42 | 32 |
Summe Anlagevermögen | 1 | 2 | 2 | 3 | 11 |
Summe Aktiva | 8 | 24 | 49 | 45 | 43 |
Bilanz (in Mio. EUR) - Passiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Fremdkapital | 13 | 8 | 10 | 18 | 22 |
Summe Eigenkapital | -5 | 16 | 40 | 27 | 20 |
Summe Passiva | 8 | 24 | 49 | 45 | 43 |
Adresse
70, Avenue Tony Garnier, 69007 Lyon | |
Telefon | +33 (4) 28-29-14-00 |
Internet | http://www.maatpharma.com |
Management
Carole Schwintner
Chief Technology Officer |
Claude Bertrand
Independent Director |
Dorothée Burkel
Independent Director |
Emilie Plantamura
Head-Clinical Development |
Eric Soyer
Chief Financial Officer |
Gianfranco Pittari
Chief Medical Officer |
Guilhaume Debroas
Head-Investor Relations |
Hervé Affagard
Chief Executive Officer & Director |
Isabelle de Cremoux
Non-Independent Non-Executive Director |
Jean Volatier
Independent Director |
Jean-Marie Lefèvre
Non-Independent Non-Executive Director |
Jonathan Chriqui
Chief Business Officer |
Karim Dabbagh
Independent Chairman |
Karine Gaudin
Deputy Director-Finance & Administration |
Muriel Prudent
Non-Executive Director |
Nadia Kamal
Independent Director |
Nathalie Corvaïa
Chief Scientific Officer |
Philippe Moyen
Chief Operating Officer |
Siân Crouzet
Chief of Staff |